EDN1 and Cirrhosis: ET-1-mediated control of HSC activation has been demonstrated in previous studies, in which pharmaceutical inhibition of AngII and ET-1 reduces HSC activation in vitro[13], [17] and in rat models of cirrhosis [15], [19].